Abstract 4553: Evaluation of cfDNA release profiles in colorectal cancer patients during surgery

IF 12.5 1区 医学 Q1 ONCOLOGY
Mailson Alves Lopes, Maria Elvira Ribeiro Cordeiro, Flávio de Alencar Teles Barreto, Lara de Souza Moreno, André Araújo Silva, Mayra Veloso Soares, Mariana Braccialli de Loyola, Joao Batista de Sousa, Fabio Pittella-Silva
{"title":"Abstract 4553: Evaluation of cfDNA release profiles in colorectal cancer patients during surgery","authors":"Mailson Alves Lopes, Maria Elvira Ribeiro Cordeiro, Flávio de Alencar Teles Barreto, Lara de Souza Moreno, André Araújo Silva, Mayra Veloso Soares, Mariana Braccialli de Loyola, Joao Batista de Sousa, Fabio Pittella-Silva","doi":"10.1158/1538-7445.am2025-4553","DOIUrl":null,"url":null,"abstract":"Surgical intervention is one of the most employed treatments for colorectal cancer, especially in patients with localized disease. However, the dynamics of circulating cell-free DNA (cfDNA) release during surgical procedures remain poorly understood. This lack of understanding underscores a significant gap regarding the biological processes underlying tumor response to surgery. Here we examined surgical cfDNA release from 30 colorectal cancer patients. cfDNA was extracted from plasma samples at three key points: preoperative (just before surgery), intraoperative (during surgery), and postoperative (at the end of surgery). Automated electrophoresis was used to analyze cfDNA concentrations and fragment sizes, which were then correlated with different clinical variables. Our findings show a significant increase in cfDNA release during and after surgery in comparison to preoperative time (2.8- and 2.2-fold higher, respectively). cfDNA fragments of <400 bp were predominant at all surgical stages, with no significant release of genomic DNA detected in any stage. We found that cfDNA concentrations increase on an average of 2 to 3-folds during and after surgery in patients over 60 years old, in patients with comorbidities and in patients with CEA levels > 5 ng/mL. Importantly, cfDNA release during surgery was significantly higher in patients with adverse clinical characteristics. Patients with locally advanced tumors or metastasis had a 3.1-fold increase in cfDNA release intraoperatively and a 2.4-fold increase postoperatively (p < 0.01). cfDNA concentrations also increase intraoperatively in patients with high tumor bud scores (2.6-fold higher, p < 0.02), perineural invasion (3.4-fold higher, p < 0.02), and lymphovascular invasion (3.1-fold higher, p < 0.05). Overall, our findings indicate that factors such as advanced physiological age, existing comorbidities, adverse clinical characteristics, and extensive surgical manipulation may contribute to increased tissue damage and enhanced cfDNA release. Citation Format: Mailson Alves Lopes, Maria Elvira Ribeiro Cordeiro, Flávio de Alencar Teles Barreto, Lara de Souza Moreno, André Araújo Silva, Mayra Veloso Soares, Mariana Braccialli de Loyola, Joao Batista de Sousa, Fabio Pittella-Silva. Evaluation of cfDNA release profiles in colorectal cancer patients during surgery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1): nr 4553.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"108 1","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.am2025-4553","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Surgical intervention is one of the most employed treatments for colorectal cancer, especially in patients with localized disease. However, the dynamics of circulating cell-free DNA (cfDNA) release during surgical procedures remain poorly understood. This lack of understanding underscores a significant gap regarding the biological processes underlying tumor response to surgery. Here we examined surgical cfDNA release from 30 colorectal cancer patients. cfDNA was extracted from plasma samples at three key points: preoperative (just before surgery), intraoperative (during surgery), and postoperative (at the end of surgery). Automated electrophoresis was used to analyze cfDNA concentrations and fragment sizes, which were then correlated with different clinical variables. Our findings show a significant increase in cfDNA release during and after surgery in comparison to preoperative time (2.8- and 2.2-fold higher, respectively). cfDNA fragments of <400 bp were predominant at all surgical stages, with no significant release of genomic DNA detected in any stage. We found that cfDNA concentrations increase on an average of 2 to 3-folds during and after surgery in patients over 60 years old, in patients with comorbidities and in patients with CEA levels > 5 ng/mL. Importantly, cfDNA release during surgery was significantly higher in patients with adverse clinical characteristics. Patients with locally advanced tumors or metastasis had a 3.1-fold increase in cfDNA release intraoperatively and a 2.4-fold increase postoperatively (p < 0.01). cfDNA concentrations also increase intraoperatively in patients with high tumor bud scores (2.6-fold higher, p < 0.02), perineural invasion (3.4-fold higher, p < 0.02), and lymphovascular invasion (3.1-fold higher, p < 0.05). Overall, our findings indicate that factors such as advanced physiological age, existing comorbidities, adverse clinical characteristics, and extensive surgical manipulation may contribute to increased tissue damage and enhanced cfDNA release. Citation Format: Mailson Alves Lopes, Maria Elvira Ribeiro Cordeiro, Flávio de Alencar Teles Barreto, Lara de Souza Moreno, André Araújo Silva, Mayra Veloso Soares, Mariana Braccialli de Loyola, Joao Batista de Sousa, Fabio Pittella-Silva. Evaluation of cfDNA release profiles in colorectal cancer patients during surgery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1): nr 4553.
摘要 4553:评估结直肠癌患者手术期间 cfDNA 的释放情况
手术干预是结直肠癌最常用的治疗方法之一,特别是对于局部病变的患者。然而,在手术过程中循环无细胞DNA (cfDNA)释放的动力学仍然知之甚少。这种理解的缺乏强调了肿瘤对手术反应的生物学过程的重大差距。在这里,我们检查了30例结直肠癌患者的手术cfDNA释放。在术前(手术前)、术中(手术中)和术后(手术结束)三个关键点提取血浆样本中的cfDNA。使用自动电泳分析cfDNA浓度和片段大小,然后将其与不同的临床变量相关。我们的研究结果显示,与术前相比,手术期间和手术后cfDNA释放显著增加(分别高出2.8倍和2.2倍)。lt;400 bp的cfDNA片段在所有手术阶段均占主导地位,在任何阶段均未检测到显著的基因组DNA释放。我们发现,在60岁以上的患者、有合并症的患者和CEA水平较高的患者中,cfDNA浓度在手术期间和手术后平均增加2 - 3倍。5 ng / mL。重要的是,在有不良临床特征的患者中,手术期间cfDNA的释放明显更高。局部晚期肿瘤或转移患者术中cfDNA释放增加3.1倍,术后增加2.4倍(p <;0.01)。高肿瘤芽评分患者术中cfDNA浓度也升高(高2.6倍,p <;0.02),神经周围侵犯(高出3.4倍,p <;淋巴血管侵袭(p <;高3.1倍);0.05)。总的来说,我们的研究结果表明,生理年龄的增加、现有的合并症、不良的临床特征和广泛的手术操作等因素可能导致组织损伤的增加和cfDNA释放的增强。引文格式:Mailson Alves Lopes, Maria Elvira Ribeiro Cordeiro, Flávio de Alencar Teles Barreto, Lara de Souza Moreno, andr Araújo Silva, Mayra Veloso Soares, Mariana Braccialli de Loyola, Joao Batista de Sousa, Fabio Pittella-Silva。结直肠癌患者手术过程中cfDNA释放谱的评价[摘要]。摘自:《2025年美国癌症研究协会年会论文集》;第1部分(常规);2025年4月25日至30日;费城(PA): AACR;中国生物医学工程学报(英文版);21(5):444 - 444。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer research
Cancer research 医学-肿瘤学
CiteScore
16.10
自引率
0.90%
发文量
7677
审稿时长
2.5 months
期刊介绍: Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research. With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445. Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信